Amicus Therapeutics is Changing Lives

Founded on February 4, 2002, Amicus Therapeutics is a public biopharmaceutical company with its headquarters located in Cranbury, New Jersey. Amicus Therapeutics was founded by a group of firms namely Radius Ventures, Canaan Partners, and New Enterprise Associates. Some of the key people in the organization include John Crowley who is the Chief Executive Officer; Bradley Campbell who is the Chief Operations Officer; and William Baird who is the Chief Financial Officer (GoogleFinance). On 2010, the powers of the Chief Scientific Officer were vested in David Lockhart.

 

At Amicus Therapeutics, they mainly focus on rare and orphan diseases, particularly the lysosomal storage disorders. These are basically metabolic diseases that are inherited and are characterized by an unusual build up of waste materials that are toxic to the body. This is attributed mainly to deficiency of certain enzymes in the body cells. Amicus Therapeutics products are based largely on the Chaperone-Advanced Replacement Therapy (CHART) platform (https://yourbeautycraze.com/amicus-therapeutics-introduces-galafold-fabry-disease-patients/). This makes the company concentrate fully on the development of enzyme replacement therapies. Apart from the Lysosomal storage disorders, the company also tries to develop therapies for the Pompe Disease and the genetic skin disorder Epidermolysis Bullosa. Amicus Therapeutics is able to conduct research and come up with possible therapies through the unique set of technologies it has.

 

Amicus Therapeutics is filled with research experts and trained medical personnel whose main goal is to make a difference in the lives of the patients and their caregivers. True to the fact, Amicus is changing lives by offering personalized care to the patients and conducting thorough research. A clear example of the progress in research the firm is making is the invention of migalastat. Migalastat is a medicine in its late stages of development. When complete, the drug is supposed to treat people suffering from the Fabry disease depending on their genetic diagnosis.

More about Amicus Therapeutics on Twitter

Leave a Reply

Your email address will not be published. Required fields are marked *